Abstract 1898P
Background
ICI rechallenge in solid tumors (including in mccRCC) after discontinuation or disease progression following a prior ICI is often practiced in the clinic and is an area of active investigation. Two ph 3 trials (NCT04338269/Contact-3 and NCT04987203/TiNivo-2) are evaluating this Rx paradigm in mccRCC. Cabo is the most common 2L Rx in mccRCC.
Methods
This study used the de-identified nationwide (US based) Flatiron Health EHR-derived database. Inclusion: diagnosis of mccRCC, receipt of 1L Rx with any ICI based Rx (between 3/2016 to 7/2022) followed by receipt of 2L Rx with cabo or cabo + PD-1i (between 6/2018 to 9/2022). Exclusion: 1L Rx with cabo, or pts with no evidence of contact for 90 days from diagnosis of mccRCC at treating institution to ensure pts were actively engaged in care. TTNT (time to next therapy; measured from 2L to 3L) and overall survival (OS; measured from 2L) were summarized via Kaplan-Meier survival estimates with 95% confidence interval (CI) and compared in the context of propensity score (PS) matching weighted analysis and Cox proportional hazard model (PSM- CoxHzM). PS model included 1L baseline covariates: age, race, smoking status, practice type, insurance, year of 1L, six IMDC risk factors, and missingness of covariates. Missing data were multiply imputed using predictive mean matching on 50 chained equations. All analysis done using R version 4.2.3.
Results
Of 12,285 mccRCC pts in the dataset, 314 pts met eligibilty. Results summarized in table.
Table: 1898P
2L cabo vs cabo-PD-1i in pts with PD-1i based therapy in 1L
Median TTNT (95% CI) mos | Median OS (95% CI) mos | |
Cabo (n=251) | 7.6 (6.9 – 8.9) | 29 (25 - 33) |
Cabo + PD-1i (n=63) | 15 (10, not reached) | 31 (25- not reached) |
PSM- CoxHzM Hazard ratio (95% CI, p-value) | 0.69 (0.45 - 1.06, 0.087) | 1.08 (0.69 - 1.68, 0.74) |
Conclusions
No benefit of adding PD-1i therapy to cabo vs cabo alone in 2 L was observed on PSM – CoxHzM. These results from a real world mccRCC pts are similar to those in a recent press-release on CONTACT-03 trial and question the practice of ICI rechallenge in mccRCC and other solid tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
U. Swami: Financial Interests, Personal and Institutional, Advisory Board, a consulting or advisory role by Seattle Genetics, Astellas Pharma, Exelixis, Imvax, and AstraZeneca, currently or during the past 2 years. Dr. Swami’s institution has received research funding from Janssen, Seattle Genetics/Astellas, and Exelixis, currently or within the past 2 years: a consulting or advisory role by Seattle Genetics, Astellas Pharma, Exelixis, Imvax, and AstraZeneca, currently or during the past 2 years. Dr. Swami’s institution has received research funding from Janssen, Seattle Genetics/Astellas, and Exelixis, Curren. B.L. Maughan: Financial Interests, Personal and Institutional, Advisory Board, paid consultant/advisor to AbbVie, Pfizer, AVEO oncology, Janssen, Astellas, BMS, Clovis, Tempus, Merck, Exelixis, Bayer Oncology and Peloton Therapeutics; Huntsman Cancer Institute has received research funding from Exelixis (Inst), Bavarian-Nordic (Inst), Clovis (Inst), Genentech (Inst) and BMS (Inst) on his behalf: paid consultant/advisor to AbbVie, Pfizer, AVEO oncology, Janssen, Astellas, BMS, Clovis, Tempus, Merck, Exelixis, Bayer Oncology and Peloton Therapeutics; Huntsman Cancer Institute has received research funding from Exelixis (Inst), Bava. N. Agarwal: Financial Interests, Personal and Institutional, Advisory Board, Consultancy to Astellas, AstraZeneca, Aveo, Bayer, BMS, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics. Research funding to Neeraj Agarwal's institution: Arnivas, Astellas, AstraZeneca, Bavarian Nordic, Bayer, BMS, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GSK, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon: Consultancy to Astellas, AstraZeneca, Aveo, Bayer, BMS, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle G. All other authors have declared no conflicts of interest.
Resources from the same session
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23
1890P - Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)
Presenter: Christopher Darr
Session: Poster session 23
1891P - Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma
Presenter: Renee Saliby
Session: Poster session 23
1892P - A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
Presenter: Rana McKay
Session: Poster session 23
1895P - Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
Presenter: Sara Elena Rebuzzi
Session: Poster session 23
1896P - Clinical management and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab+ipilimumab (N+I): A real-world study
Presenter: Tom Geldart
Session: Poster session 23
1897P - Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Presenter: Francesco Massari
Session: Poster session 23
1899P - Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab + nivolumab (ipi+nivo) vs. PD-1/L1 inhibitor (PDI) + tyrosine kinase inhibitor (TKI)
Presenter: Georges Gebrael
Session: Poster session 23
1900P - Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the national cancer database (2004-2020)
Presenter: ALINA BASNET
Session: Poster session 23